International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE	PSYCHEDELICS IN THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER AND DEPRESSION: A REVIEW OF CLINICAL TRIALS
DOI	https://doi.org/10.31435/ijitss.3(51).2026.6062
RECEIVED	08 June 2026
ACCEPTED	23 August 2026
PUBLISHED	31 August 2026
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

PSYCHEDELICS IN THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER AND DEPRESSION: A REVIEW OF CLINICAL TRIALS

Anna Maria Szeszko *(Corresponding Author, Email: annaszeszko00@gmail.com)*
University Clinical Hospital No. 2, Medical University of Lodz, Poland
ORCID ID: 0009-0008-2062-2188

Weronika Maria Czernek
University Clinical Hospital No. 2, Medical University of Lodz, Poland
ORCID ID: 0009-0009-0457-8970

Magdalena Cichorzewska
University Clinical Hospital No. 2, Medical University of Lodz, Poland
ORCID ID: 0009-0005-0701-8742

Martyna Płachta
University Clinical Hospital No. 2, Medical University of Lodz, Poland
ORCID ID: 0009-0008-2471-598X

Rafał Marcin Wojtan
Nikolay Pirogov Specialized District Hospital, Lodz, Poland
ORCID ID: 0009-0000-9647-2245

Małgorzata Lubowiecka
4th Military Clinical Hospital and Polyclinic IPHC, Wroclaw, Poland
ORCID ID: 0009-0005-0424-2095

ABSTRACT

Psychedelic-assisted therapy has emerged as a prominent area for psychiatric investigation particularly with regards to treatment-resistant depression and Post Traumatic Stress Disorder (PTSD). The purpose of this narrative review was to outline the current body of research regarding psychedelic and psychedelic-like compounds in these two psychiatric conditions highlighting psilocybin-assisted therapy for depression and 3,4-methylenedioxymethamphetamine-assisted therapy for PTSD. Searches for this review focused on clinical trials, follow-up studies, systematic reviews and regulatory documentation published between 2016 and June 2026 that had been peer-reviewed. Evidence from this review confirms that psilocybin when used alongside a therapeutic intervention produces prompt reduction of symptoms for depression in Major depressive disorder, treatment-resistant depression, and psychological distress associated with cancer. There was also evidence of clinically significant reduction of symptoms with trials using 3,4-methylenedioxymethamphetamine for the treatment of PTSD with two phase three trials showing robust reduction in symptom scores compared to placebo-plus-therapy. The current body of evidence, however, is not as extensive or as simple as has been suggested, and has several limitations: low sample sizes in multiple studies, difficulty in functioning blinded treatment groups, expectations in patients and therapists, inadequate length of follow up, a lack of demographic diversity in participants, high treatment requirements, a developing understanding of appropriate models of psychotherapy, and several unsolved safety and regulatory questions. Psychedelic-assisted therapy is therefore an emerging intervention that has potential but it has yet to be properly understood and its future is dependent on well-conducted studies, transparent disclosure of adverse events, careful patient selection, proper therapist training, long-term assessment, and health systems that are equipped to deliver treatment safely and equitably.

KEYWORDS

Psychedelic-Assisted Therapy, Psilocybin, Post-Traumatic Stress Disorder, Depression, Clinical Trials, Mental Health

CITATION

Anna Maria Szeszko, Weronika Maria Czernek, Magdalena Cichorzewska, Martyna Płachta, Rafał Marcin Wojtan, Małgorzata Lubowiecka. (2026) Psychedelics in the Treatment of Post-Traumatic Stress Disorder and Depression: a Review of Clinical Trials. *International Journal of Innovative Technologies in Social Science*. 3(51). doi: 10.31435/ijitss.3(51).2026.6062

1. Introduction

Depression and PTSD are two of the most disabling of mental disorders worldwide, with typical features including a chronic and recurrent course, functional impairment, physical comorbid illness, suicide risk and low quality of life. These concerns have been raised by the World Health Organization (2022), and it is accepted widely within clinical psychiatry that current treatments result in non-remission for a substantial proportion of those suffering from depression and PTSD. While established evidence-based treatments, such as antidepressants, trauma-focused psychotherapies and others, remain the mainstays of treatment, they provide a limited response at best. The response to treatment can also be slow and difficult to sustain. Interest has been renewed in treatments that could work via new psychological and biological pathways, as a result of this treatment deficit.

Renewed interest has focused on the use of psychedelic-assisted therapy, although this remains a broad and heterogeneous concept. These classic psychedelics (such as psilocybin, LSD, DMT) tend to target the serotonergic system with significant focus on the serotonin 2A receptor system. There is a great deal of interest in drugs such as MDMA although it is classified as an entactogen or empathogen pharmacologically but is treated in the same clinical field. It is this research that holds the highest level of clinical trial evidence for PTSD, whereas psilocybin assisted therapy holds the strongest systematic testing evidence for depression. For the purposes of this review, the term “psychedelic-assisted therapy” will be used to encompass both classic psychedelics and MDMA-assisted interventions where appropriate.

However, the current treatment is much more than just administering the medication. All, or nearly all, published clinical trials conducted to date on these medicines combine the medication with a "psychological component" which includes pre-therapy preparation sessions, a closely monitored "dosing session" in which the medicine is administered, and post-session integration procedures. Theoretically, it is hoped that a profound shift in emotional processing, threat, self-referential processing, autobiographical memory and psychological flexibility would occur during a "window" in which the psychotherapy would be more effective. The effects of MDMA on PTSD may include reductions in aversion, defensiveness, and fear while increasing trust and affect tolerance; it may be hypothesized that psilocybin's effects in depression may promote the loosening of fixed patterns of thought (rumination) and encourage a change in values, perspectives and behaviors. None of these proposed mechanisms have been adequately explored or confirmed.

It may be tempting to conclude that psychedelic-assisted therapy is approaching mainstream clinical application; however, the evidence remains more nuanced. While results can be striking, very successful placebo-controlled trials have been difficult to run. The study populations are highly selected and extensively supported, and treatment sessions are lengthy and resource-intensive, requiring highly trained professionals. In this review the clinical evidence for PTSD and depression in terms of efficacy, safety and limitations will be explored, as will practical considerations.

2. Materials and Methods

This article was generated as a narrative review of clinical trials and clinically pertinent evidence related to psychedelic-assisted therapy in the treatment of PTSD and depression. Human clinical trial research-rather than preclinical animal models or purely neurobiological theoretical frameworks-formed the core of the review. Searches of PubMed, Google Scholar, journal websites, and regulatory sites were conducted using combinations of the terms psychedelic-assisted therapy, psilocybin, depression, major depressive disorder, treatment-resistant depression, post-traumatic stress disorder, MDMA-assisted therapy, randomized clinical trial, phase 2, phase 3, safety, adverse events, and regulation. Prioritization was given to randomized clinical trials, phase 2 and phase 3 trials, prospective follow-up reports, systematic reviews, and meta-analyses.

Foundational clinical studies from 2016 and later were included since they formed the basis of the modern era of research in these indications and continue to inform the design of subsequent trials. More recent data were prioritized when they involved larger patient populations, discussed the role of regulation, or

presented recent findings regarding safety. Studies reporting exclusively on recreational use, uncontrolled naturalistic use without clinical follow-up or monitoring, or trials solely with healthy volunteers or focusing exclusively on mechanisms without clinical endpoints were excluded. Because of the rapid nature of field development and the limited number of large-scale trials, a narrative rather than formal meta-analytic approach was deemed appropriate.

This study aims to convey a sense of the overall clinical landscape, highlight differential evidence strengths across PTSD and depression, and draw attention to methodological and implementational issues pertinent to the clinician, researcher, and policymaker. No new patient data were collected, therefore, no Institutional Review Board approval was needed.

3. Evidence Synthesis

There are two areas of clinical maturity that emerge from the review. Regarding PTSD, the majority of clinical evidence is focused around MDMA-assisted psychotherapy, in particular the two large multisite phase 3 trials, conducted by Mitchell et al. Regarding depression, the most robust clinical evidence surrounds psilocybin-assisted psychotherapy for MDD, treatment-resistant depression, and cancer distress. The other psychedelic compounds such as ayahuasca and short-acting DMT, demonstrate initial clinical evidence for depression, however are not as mature or as relevant to PTSD.

3.1 Therapeutic Model and Mechanisms Relevant to Clinical Trials

Clinical trials are more often than not, employing a package of care rather than drugs only protocol, screening subjects psychiatrically and physically, "priming" the subjects with information before administering the drugs, closely supervising them in the acute period, and integrating them into daily life. These are all essential elements, therefore it is not possible to say it was purely the pharmacological effect of the compound that brought about the observed effects and that setting, therapeutic alliance, music, expectations, preparation, and integration could contribute equally. Many clinical trials compare drug administration with placebo plus the same amount of psychotherapy but double-blind conditions cannot always be achieved due to the fact that the psychedelic effects are rather easy to distinguish.

Proposed mechanisms for the effectiveness of psilocybin for depression include: increased emotionality and openness, disruption of self-referential rumination and inflexibility, neural re-wiring and increase in psychological flexibility. Clinical reports frequently describe psilocybin experiences as emotionally intense rather than simply mood-elevating. Perhaps this can explain the rapid improvement in antidepressant symptoms found in some studies after just one or two dosing sessions, but a deeply meaningful experience does not equate to an enduring clinical outcome and future studies need to more carefully account for the drug, therapy and expectancy components.

With MDMA in PTSD, the model of therapeutic mechanism is quite different. The classic psychedelic perceptual changes that are experienced with psilocybin rarely, if ever, occurs with MDMA; the clinical importance lies in the reduction in fear, increase in social connectedness, the increase in tolerance to recall of traumatic material, and the increase in confronting trauma. Avoidance is a critical perpetuating mechanism in PTSD, and such features would theoretically promote therapy. Clinically the questions are, does combination therapy with placebo plus intensive psychotherapy provide any additional benefit to placebo plus intensive therapy, and is that benefit reproducible in a bias controlled and risk managed context.

3.2 MDMA-Assisted Therapy for Post-Traumatic Stress Disorder

The strongest clinical evidence currently available for PTSD comes from the MDMA-assisted therapy literature. A Phase III trial (first ever for MDMA, protocol initiated by Mitchell et al, 2021) looked at adult patients with moderate to severe PTSD, and randomized participants to either a 3-session MDMA or placebo assisted, manualized psychotherapy. MDMA therapy yielded significant clinical improvement in symptom and functional impairment relative to placebo, and one advantage of the study was the relatively broad range of commonly occurring conditions participants could have, making it more representative of clinical population patients than a highly exclusive efficacy study.

A later phase 3 confirmatory study further explored MDMA assisted therapy in the treatment of moderate to severe PTSD with more of a diverse patient population (Mitchell et al., 2023). It also found more improvement of PTSD symptoms and functional impairment compared to placebo + therapy. Both of these studies are very important because they were among the first in this field to move from small pilot studies to providing a type of evidence used to make regulatory decisions and show that MDMA assisted therapy has a capability of producing clinically relevant treatment for PTSD when in a highly controlled setting.

This signal is only partially confirmed by the systematic review data; Shahrour et al (2024) stated that MDMA-assisted psychotherapy showed significant increases in chronic PTSD symptom reduction and in response and remission rates compared to the comparators. Literature still requires more trials. The existence of several large positive trials is encouraging; however it does not make studies on replication, with long-term follow up and assessment of side-effects unnecessary.

Also to show how methodologically complex the psychedelic research has been, consider the MDMA data. A key problem is the functional unblinding of therapists and patients who can likely decipher who is getting what from acute effects on the patient. In the case of patients receiving active drug, this can increase the effects of placebo response and vice-versa. This does not negate the effects of treatment but it makes the analysis complex. In relation to PTSD, expectancy effects and therapeutic alliance are important and the level of support and expectations of treatment should be factored into interpretation.

Additional concerns related to regulatory issues also support a more cautious stance. In the United States, the FDA issued a Complete Response Letter in 2024, regarding the application for MDMA-assisted therapy. It required further evidence before granting approval (U.S. Food and Drug Administration, 2024), though it seems the positive findings regarding positive symptoms were not in doubt. Rather, clinical effectiveness, side-effect monitoring, trial procedures and data integrity required a higher burden of proof to achieve wide adoption. In Australia, registered psychiatrists are able to access MDMA for PTSD, although use of this method of treatment is confined and subject to strict regulations and is not part of typical psychiatric treatment (Therapeutic Goods Administration, 2024).

3.3 Psilocybin-Assisted Therapy for Depression

Psilocybin forms the underpinning of treatment for depression. Early studies of life related distress in terminally ill cancer patients during the early modern era are of primary importance in providing a proof of concept showing that one intense psilocybin support session leads to significant reduction in levels of depression and anxiety in terminally ill cancer patients. The study carried out by Ross et al. (2016) also noted a statistically significant, sustained and rapid decrease in both cancer related anxiety and depression following a course of psilocybin assisted therapy. This effect has been repeated and replicated during a number of studies and, similar findings showing both sustained, significant, decrease in anxiety and depression among terminally ill cancer patients after psilocybin therapy was seen in a study carried out by Griffiths et al. (2016). Although not trials on a general sample, these early trials have clearly demonstrated the ability of psilocybin to induce clinically relevant reductions in intense emotional suffering in a controlled therapeutic context.

The area then developed into treating major depressive disorder. A randomized control study using psilocybin-assisted psychotherapy for adults experiencing major depressive disorder concluded that there were significant, rapid and durable antidepressant effects, a subsequent prospective follow-up study into this trial showed that it could be up to 12 months for the effects to be lasting in some of the patients (Gukasyan et al., 2022). Although encouraging, the study was limited by its small sample size and extensive psychotherapeutic support.

The comparison with standard antidepressant treatment has been addressed directly. Carhart-Harris et al. (2021) compared psilocybin therapy with escitalopram in a double-blind randomized trial. The primary outcome did not show a statistically significant difference between groups, although several secondary outcomes favored psilocybin. This trial is important because it introduced an active antidepressant comparator rather than only placebo. It also showed how interpretation becomes more complex when trials move from proof-of-concept designs to clinically realistic comparisons.

The phase 2 evidence base has continued to build, but also has more nuances. Goodwin et al. (2022) looked at one dose of synthetic psilocybin in treatment-resistant depression and found that while a 25 mg dose significantly decreased depressive symptoms in comparison to a 1 mg placebo dose at three weeks, a 10 mg dose did not. There were adverse events, however, with two individuals experiencing suicidal ideation and two with self-harm in the treatment resistant group, confirming the importance of monitoring participants carefully. Raison et al. (2023) similarly found that a single 25 mg dose of psilocybin with psychological support, demonstrated statistically and clinically significant reductions in measures of major depressive disorder and functional impairment in comparison to active placebo.

Further studies have also lent support to the possibility of the durability of treatment effect being overestimated and has served as a reminder to the community that it can. In one trial, von Rotz et al. (2023) observed that two weeks after one moderate dose of psilocybin depressive symptoms were significantly improved when compared to placebo and there were no severe adverse events. Although this study provided an encouraging result that the single dose of psilocybin is a signal for an acute antidepressant, the durability of the treatment effect has not been determined. For example, we do not know if one or two doses would be the cause of remissions lasting years. Depression is generally a recurrent disorder and response cannot be interpreted as remission lasting years.

3.4 Ayahuasca, Dimethyltryptamine and the Wider Depression Literature

Psilocybin is by far the most widely explored in depression trials, but other psychedelic substances are also being explored. For example, Palhano-Fontes et al. (2019) showed fast antidepressant effects from ayahuasca use in a randomized placebo-controlled study of treatment-resistant depression. The finding of clinical relevance as ayahuasca is an antidepressant that is composed of dimethyltryptamine, different from psilocybin pharmacologically and culturally but less well-researched, with a treatment context more appropriate for cross-site standardization.

Short-acting dimethyltryptamine is another that could be of interest, as the duration of acute effects is much shorter than that for psilocybin, which could mitigate the potential burden of having patients spend their entire day in dosing. The research is in very early stages, and is not evidence for clinical efficacy. Hence the depression literature would be indicative of a general class effect, and of possible antidepressant effects of serotonergic psychedelics, but psilocybin is at the moment, the most clinically progressed classic psychedelic for the treatment of depression.

The result of these systematic reviews and meta-analyses points towards careful optimism. Ko et al. (2023) reported positive effects of psychedelic therapy for depression; however, they also highlighted small samples and the lack of rigorous RCT's. Similarly Haikazian et al. (2023) found that psilocybin-assisted therapy holds antidepressant promise, however again they pointed out the current shortcomings in evidence. This is not to suggest that psychedelic therapy will "cure" treatment-resistant depression. However, the antidepressant signal is sufficient to warrant large phase III clinical trials**.**

3.5 Safety and Adverse Events

Psychological safety in psychedelic assisted therapy is multifaceted. Side effects to an acute psychedelic experience are as diverse as anxiety, panic, confusion, emotional upset and temporary exacerbation of traumatic memories. These side effects are anticipated to an extent with psychedelic assisted therapy, but trained accompaniment is important and should not be underestimated. Side effects on a physiological level differ between substances. MDMA may result in rises in heart rate and blood pressure, and raises cardiovascular concerns. Psilocybin is known to increase blood pressure temporarily, causes nausea and acute anxiety. Both methods require rigorous pre-treatment screening, monitoring, and clear guidelines for an emergency.

The issue of psychiatric safety is even more pronounced in depression and PTSD since it may be accompanied by suicidal ideation, dissociation, history of substance use, and trauma related vulnerability. Adverse events related to suicidality must be interpreted judiciously in the context of antidepressant trials for treatment-resistant depression. While they may reflect pre-existing risk among severely depressed participants they clearly show why psychedelic treatment cannot be provided in a non-clinical setting. The Goodwin et al (2022) study is particularly significant as it reported both antidepressant effects and safety concerns that must be given due consideration.

Therapist behavior and boundaries are safety concerns too. Since these states can amplify vulnerability, suggestibility and the tendency toward dependence, the therapist is placed in the position of protector against manipulation, boundary violations and the unintended, harmful therapeutic influence of an enhanced suggesting agent. Safety, therefore, is not simply a pharmacological issue, but is critically dependent on a trained and supervised ethical practitioner and the accountable institutions that support her or him. A program that is unable to offer such protections should not be engaged in the delivery of this therapy.

3.6 Tables

The following tables summarize the clinical trial evidence and the main implementation issues identified in this review.

Table 1. Selected clinical trial evidence for psychedelic-assisted therapy in PTSD and depression.

Condition	Intervention	Representative evidence	Main finding	Main caution
PTSD	MDMA-assisted therapy	Mitchell et al. (2021, 2023); Shahrour et al. (2024)	Large reductions in PTSD symptoms and functional impairment in phase 3 trials	Functional unblinding, regulatory concerns and need for additional evidence
Major depressive disorder	Psilocybin-assisted therapy	Davis et al. (2021); Raison et al. (2023); von Rotz et al. (2023)	Rapid reductions in depressive symptoms after one or two supported dosing sessions	Durability, expectancy effects and generalizability remain uncertain
Treatment-resistant depression	Psilocybin	Goodwin et al. (2022); Palhano-Fontes et al. (2019)	Promising antidepressant effects in difficult-to-treat samples	Safety monitoring is essential, particularly around suicidality
Cancer-related depression and anxiety	Psilocybin-assisted psychotherapy	Ross et al. (2016); Griffiths et al. (2016)	Sustained reductions in existential distress, depression and anxiety	Population differs from general depression and sample sizes were modest

Table 2. Key clinical and methodological challenges in psychedelic-assisted therapy trials.

Challenge	Why it matters	Possible response
Functional unblinding	Participants and therapists may infer allocation from drug effects	Measure expectancy, use active controls and blinded independent raters
Short follow-up	Early response may not equal durable remission	Include 6-, 12- and 24-month outcomes where possible
Safety and suicidality	Depression and PTSD samples may already be high risk	Use careful screening, monitoring and crisis protocols
Therapist training	Patients are vulnerable during altered states	Standardize training, supervision and ethical boundaries
Access and cost	Long sessions may restrict treatment to privileged settings	Plan workforce, reimbursement and scalable service models

3.7 Interpretation of Evidence Quality

Overall the evidence is good, but not yet fully mature for both PTSD and depression. A positive aspect of the literature is that many of the trials were designed as randomized controlled trials and used reliable measures of symptoms, as well as providing structured psychological support. In relation to PTSD, the most positive development is the presence of 2 phase 3 trials. The most positive development in depression research is the development from a range of small proof of concept studies to larger phase 2 studies and comparisons with active control condition. This differentiates it from earlier periods of psychedelic enthusiasm which were often based upon case studies and uncontrolled observation.

Simultaneously, standard evidence hierarchies are a poor fit with psychedelic-assisted treatment. The treatment consists of an intense subjective experience, and in doing so, it is uniquely hard to perform a double-blind placebo trial. In normal antidepressant trials it is possible that the blinding may not be completely effective, but that most participants cannot distinguish their assigned treatment. In a psychedelic trial, the acute experience is so intense that assignment to placebo or active treatment may be blindingly obvious. As such, the improvement noted in symptoms may be the result of pharmacology, psychotherapy, expectation, therapeutic alliance, and the personal interpretation that the experience has taken. The goal for future studies is not to deny these other effects, but to quantify and interpret them.

Information is also required about which populations would most benefit. There are many inclusion criteria that can be applied to clinical trials such as those that exclude patients with psychotic disorders, uncontrolled bipolar disorder, medical instability, and those at high risk for acute suicidality. Although reasonable from a clinical standpoint, inclusion criteria can limit the generalization of trial data to all individuals with depression or PTSD. The patient interested in psychedelic therapy might be an individual who has significant comorbidities, significant trauma exposure, and extensive treatment histories; there is limited evidence regarding these populations.

Clinical outcomes should also go beyond change in scale scores at the end of the study. While scales were used to measure symptoms for PTSD, function, interpersonal relationships, sleep, substance use, and trauma avoidance were all critically important to patients with PTSD. Similarly, while scales were also used to assess symptoms in depression, relapse, work functioning, social life and overall quality of life were just as important as short-term scale improvements in depression trials. Therefore, future trials should include patient-reported outcomes in addition to symptom scores, and real-world functioning as measured by objective as well as patient report scales. Information concerning the psychotherapy model should be clearly presented in treatment study reports. Otherwise, we do not know if positive results were due to an effective psychotherapy, or to a very specific, well-trained research group.

4. Discussion

The evidence presented in this review suggests that psychedelic-assisted therapy may be among the most exciting and difficult of the most recent changes in modern psychiatry. The clearest signal appears for MDMA-assisted therapy in PTSD and for psilocybin-assisted therapy in depression. In both areas, reports are of swift and, at times, dramatic symptom reductions. This may be clinically significant due to the chronicity or intractable nature of the illness in many of the study participants.

Nevertheless, these findings must be interpreted with caution. Psychopharmacology trials (especially with psychedelics) are prone to expectation effects, as there is considerable difficulty in blinding participants to the presence of active drug. The patients are often aware, as is often the therapist, affecting both patient's reported symptoms, his or her engagement in therapy, and therapist-rated outcomes. Active placebos and low-dose comparators assist, but do not eliminate, the problem. Future trials need more rigorous blinding assessments, independent raters, longer follow-up and transparent reporting of protocol deviations and adverse events.

Another potential problem is that psychedelic assisted psychotherapy is a resource intensive therapy. Typically, a course of treatment could require several preparation sessions, at least one dosing session lasting several hours, at least two therapist/monitors, and integration sessions and follow-up visits. This model of care is quite different from prescribing an oral medication. Should these therapies become more generally approved, health care systems will have to face the question of who administers this therapy, how will the practice be regulated and standardized, and how will the costs be made more accessible? Unchecked, psychedelic assisted psychotherapy may very well only be made available to the privileged few at niche, urban centers.

Also unanswered is the role of psychotherapy. In trials psychotherapy is usually manualized. But there is not yet consensus in this area on which elements are necessary. We do not know if the effects are related primarily to the medicine, the psychological preparation, the experience of acute use, or the process of integration, or interaction between these elements. This question is not trivial. If psychotherapy is important then regulatory and reimbursement frameworks must consider not just the product drug, but the entire model of treatment.

Regarding PTSD, the MDMA results were excellent, but controversial from both political and scientific viewpoints. Hesitation by regulatory bodies in the USA demonstrates that a positive symptom outcome is insufficient in the presence of questions regarding blinding, trial execution and the long-term safety profile. Regarding depression, work with psilocybin is accelerating but evidence is still quite heterogeneous depending on the population, comparator and length of follow up. A prudent conclusion is that psychedelic-assisted therapy has the potential to be an important option for patients, but not as a simple panacea or alternative for existing treatments.

5. Practical Implications for Clinical Practice

The first consequence for the clinic would be very careful screening. Those who are acutely manic or psychotic, who have unstable cardiovascular problems, or who represent a very immediate suicide risk would not be good candidates for clinical trials and would need very careful screening in a clinical service. Those with depression or PTSD may seek the treatment due to press hype but the difference between controlled clinical trials and unsupported use must be clarified for the patient. There is no equivalence between recreation or personal psychedelics and psychedelic-assisted therapy.

Secondly, informed consent would have to be very thorough. Patients must realize that the benefits may be immediate but may not happen, that intensely unpleasant experiences may occur, that the longevity of effect is unclear and that intensely emotional material may be discussed. It should also include data security, roles and physical touch policy, emergency procedures, and ongoing support.

Third, clinical teams will have to be trained beyond normal drug management. Psychedelic-assisted therapy will require skills in pharmacology, trauma-informed therapy, risk assessment, altered states of consciousness, integration and ethical considerations. Institutions will need appropriate reporting mechanisms, supervision and QA policies.

6. Limitations of This Review

The review has several limitations**.** This review is a narrative one and not a systematic review or meta-analysis, nor does it contain any pooled effect sizes. The literature search was comprehensive but without a defined, reproducible protocol and flow diagram, nor did it contain formal scoring of the risk of bias. Accordingly, the conclusions should be taken as a clinically oriented appraisal rather than a precise quantitative estimate.

The evidence base is also changing at a pace. Other trials are ongoing, regulatory processes are evolving and new long-term data could modify the balance of benefits and risks. Many of the trials currently available have highly selected participants, are performed by specialist research groups and involve significant support. Such findings can be difficult to extrapolate to normal clinical practice.

An additional limitation relates to the underlying evidence base itself. Many psychedelic-assisted therapy studies have been conducted in highly selected patient populations, often with extensive exclusion criteria and substantial therapeutic support. Furthermore, publication bias cannot be excluded, particularly in a rapidly developing field where positive findings may be more likely to be published than negative or inconclusive results. Some studies have also been conducted or supported by organizations with a strong interest in the development and implementation of psychedelic therapies, highlighting the importance of independent replication and transparent reporting of both efficacy and adverse events.

7. Future Directions

Future studies need to be larger, independent and diverse RCTs. The need for diversity is particularly acute in psychedelics where trials to date have excluded patients from ethnic minorities, lower socio-economic groups and rural communities and who have high numbers of comorbidities. If the treatment is ever to be used in clinical practice then research must report on the types of patients treated in routine mental health services. Better controls, clear reporting of expectancy and blinding, independent raters and more standardized and detailed harms reports will be required. Longitudinal studies are necessary to see if early responses are maintained in depression for instance and in PTSD what benefits are seen on outcomes other than scales such as improved functioning and relationships and the absence of trauma-related avoidance, and whether the therapy leads to improvement in quality of life.

Implementation studies will be as important as efficacy studies, in terms of how the therapies are to be provided outside research centers (training, supervision, costs, legality, access, insurance coverage) and that an appropriate ethical framework exists to help protect the individual in altered states and that enthusiasm is not ahead of evidence.

8. Conclusions

Psychedelic-assisted therapies represent one of the most actively investigated developments in contemporary psychiatric research. Phase 3 studies have demonstrated substantial efficacy under controlled research conditions for MDMA-assisted psychotherapy in patients with PTSD. It also has shown promise as a rapidly acting antidepressant in major depressive disorder, treatment-resistant depression, and distress due to cancer. This is a strong basis for ongoing research, which could lead to new therapeutic options for patients unresponsive to current treatments. However, many obstacles remain in translating this research to widespread clinical application. Blinding issues, expectancy effects, a lack of long-term data, safety concerns, required therapist training, and regulatory ambiguity preclude the broad generalizability of these results for now.

Psychedelic-assisted psychotherapy should not be viewed as a simple drug treatment, but as a sophisticated and nuanced clinical model involving a combination of pharmacology, psychotherapy, preparation, monitoring, and integration. If done correctly, it has the potential to add an entirely new and effective option to our mental health armamentarium, although scientific rigor and ethical discipline, as well as the necessary infrastructure for patient safety, innovation and research, must take precedence.

REFERENCES

1. Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. *New England Journal of Medicine, 384*(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994
2. Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. *JAMA Psychiatry, 78*(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285
3. Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., . . . Malievskaia, E. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. *New England Journal of Medicine, 387*(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443
4. Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *Journal of Psychopharmacology, 30*(12), 1181–1197. https://doi.org/10.1177/0269881116675513
5. Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. *Journal of Psychopharmacology, 36*(2), 151–158. https://doi.org/10.1177/02698811211073759
6. Haikazian, S., Chen-Li, D., Johnson, D. E., Fancy, F., Levinta, A., Husain, M. I., Mansur, R. B., Rosenblat, J. D., Lipsitz, O., Lee, Y., Rodrigues, N. B., Cha, D. S., Gill, H., McIntyre, R. S., & Lui, L. M. W. (2023). Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. *Psychiatry Research, 329*, 115531. https://doi.org/10.1016/j.psychres.2023.115531
7. Ko, K., Knight, G., Rucker, J. J., & Cleare, A. J. (2023). Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. *Journal of Affective Disorders, 322*, 194–204. https://doi.org/10.1016/j.jad.2022.09.168
8. Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot'alora G., M., Garas, W., Paleos, C., Gorman, I., Nicholas, C. R., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., . . . Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. *Nature Medicine, 27*(6), 1025–1033. https://doi.org/10.1038/s41591-021-01336-3
9. Mitchell, J. M., Ot'alora G., M., van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., Paleos, C., Nicholas, C. R., Quevedo, S., Balliett, B., Hamilton, S., Mithoefer, M., Kleiman, S., Parker-Guilbert, K., Tzarfaty, K., Harrison, C., de Boer, A., Doblin, R., & Yazar-Klosinski, B. (2023). MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial. *Nature Medicine, 29*(10), 2473–2480. https://doi.org/10.1038/s41591-023-02565-4
10. Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osorio, F. L., Sanches, R., Dos Santos, R. G., Tofoli, L. F., de Oliveira Silveira, G., Yonamine, M., Riba, J., Santos, F. R., Silva-Junior, A. A., Alchieri, J. C., Galvao-Coelho, N. L., Lobao-Soares, B., . . . Araujo, D. B. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. *Psychological Medicine, 49*(4), 655–663. https://doi.org/10.1017/S0033291718001356
11. Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O'Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., . . . Griffiths, R. R. (2023). Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial. *JAMA, 330*(9), 843–853. https://doi.org/10.1001/jama.2023.14530

12. Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. *Journal of Psychopharmacology, 30*(12), 1165–1180. https://doi.org/10.1177/0269881116675512
13. Shahrour, G., McKinnon, M. C., Gorman, C., & Frewen, P. (2024). MDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis. *Neuropsychopharmacology Reports, 44*(4), 507–520. https://doi.org/10.1002/npr2.12485
14. Therapeutic Goods Administration. (2024). *MDMA and psilocybine hub*. Australian Government Department of Health and Aged Care. https://www.tga.gov.au/resources/explore-topic/mdma-and-psilocybine-hub
15. U.S. Food and Drug Administration. (2024). *Complete response letter: NDA 215455, midomafetamine capsules*. https://download.open.fda.gov/crl/CRL_NDA215455_20240808.pdf
16. von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. *eClinicalMedicine, 56*, 101809. https://doi.org/10.1016/j.eclinm.2022.101809
17. World Health Organization. (2022). *World mental health report: Transforming mental health for all*. https://www.who.int/publications/i/item/9789240049338